Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE Alfresa to Reduce SGA Expanses Ratio to Below 6% by FY2009
July 30, 2007
-
ARCHIVE MEDICAL DEVICE NEWS IN BRIEF
July 30, 2007
-
ARCHIVE BUSINESS NEWS IN BRIEF
July 30, 2007
-
ARCHIVE Benefits for OTC-Like Ethical Drugs to Be Reviewed in 4 to 5 Years
July 30, 2007
-
ARCHIVE 11 Generic Products (6 APIs) to Be Listed in November
July 30, 2007
-
ARCHIVE SELF-MEDICATION NEWS IN BRIEF
July 30, 2007
-
ARCHIVE NPhA to Further Promote Use of Generics
July 30, 2007
-
ARCHIVE OPINION/Once in a Lifetime
July 30, 2007
-
ARCHIVE MD Studies to Be Permitted at a Total Dose of 500 μg: Dr Ohno
July 30, 2007
-
ARCHIVE TOPICS/Mebix Starts Home Blood Pressure Management Service
July 30, 2007
-
ARCHIVE RIKEN, Harvard Univ. Hospital Decipher Protein Structure of LTC4 Synthase
July 30, 2007
-
ARCHIVE Nutrition Management Improves QOL, Reduces Costs: Prof. Ohyanagi
July 30, 2007
-
ARCHIVE NanoCarrier Obtains Patent on Macromolecular Micelles
July 30, 2007
-
ARCHIVE Adiponectin Stimulates Appetite in the Brain: Prof. Kadowaki
July 30, 2007
-
ARCHIVE R&D NEWS IN BRIEF(1)
July 30, 2007
-
ARCHIVE Schizophrenia Patients Must Be Treated with Fewer Drugs, at Lower Doses: Seminar
July 30, 2007
-
ARCHIVE R&D NEWS IN BRIEF(2)
July 30, 2007
-
ARCHIVE Revised Therapeutic GL on Breast Cancer Published
July 30, 2007
-
ARCHIVE NEW PRODUCTS
July 30, 2007
-
ARCHIVE Eisai to Launch 3 Major Drugs by FY2011: Mr Naito
July 30, 2007
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…